TY - JOUR
T1 - Predicted structure of MIF/CD74 and RTL1000/CD74 complexes
AU - Meza-Romero, Roberto
AU - Benedek, Gil
AU - Leng, Lin
AU - Bucala, Richard
AU - Vandenbark, Arthur A.
N1 - Funding Information:
This work was supported by the National Institutes of Health grant NS047661 and National Multiple Sclerosis Society grant RG-5068-A-6 (AAV); National Institutes of Health grants AR049610 and AI042310 (LL, RB); National Multiple Sclerosis Society grant RG5272A1/T (GB); and the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development (AAV). The contents do not represent the views of the Department of Veterans Affairs or the United States Government.
Publisher Copyright:
© 2016, Springer Science+Business Media New York (outside the USA).
PY - 2016/4/1
Y1 - 2016/4/1
N2 - Macrophage migration inhibitory factor (MIF) is a key cytokine in autoimmune and inflammatory diseases that attracts and then retains activated immune cells from the periphery to the tissues. MIF exists as a homotrimer and its effects are mediated through its primary receptor, CD74 (the class II invariant chain that exhibits a highly structured trimerization domain), present on class II expressing cells. Although a number of binding residues have been identified between MIF and CD74 trimers, their spatial orientation has not been established. Using a docking program in silico, we have modeled binding interactions between CD74 and MIF as well as CD74 and a competitive MIF inhibitor, RTL1000, a partial MHC class II construct that is currently in clinical trials for multiple sclerosis. These analyses revealed 3 binding sites on the MIF trimer that each were predicted to bind one CD74 trimer through interactions with two distinct 5 amino acid determinants. Surprisingly, predicted binding of one CD74 trimer to a single RTL1000 antagonist utilized the same two 5 residue determinants, providing strong suggestive evidence in support of the MIF binding regions on CD74. Taken together, our structural modeling predicts a new MIF(CD74)3 dodecamer that may provide the basis for increased MIF potency and the requirement for ~3-fold excess RTL1000 to achieve full antagonism.
AB - Macrophage migration inhibitory factor (MIF) is a key cytokine in autoimmune and inflammatory diseases that attracts and then retains activated immune cells from the periphery to the tissues. MIF exists as a homotrimer and its effects are mediated through its primary receptor, CD74 (the class II invariant chain that exhibits a highly structured trimerization domain), present on class II expressing cells. Although a number of binding residues have been identified between MIF and CD74 trimers, their spatial orientation has not been established. Using a docking program in silico, we have modeled binding interactions between CD74 and MIF as well as CD74 and a competitive MIF inhibitor, RTL1000, a partial MHC class II construct that is currently in clinical trials for multiple sclerosis. These analyses revealed 3 binding sites on the MIF trimer that each were predicted to bind one CD74 trimer through interactions with two distinct 5 amino acid determinants. Surprisingly, predicted binding of one CD74 trimer to a single RTL1000 antagonist utilized the same two 5 residue determinants, providing strong suggestive evidence in support of the MIF binding regions on CD74. Taken together, our structural modeling predicts a new MIF(CD74)3 dodecamer that may provide the basis for increased MIF potency and the requirement for ~3-fold excess RTL1000 to achieve full antagonism.
KW - Binding residues
KW - Inflammation
KW - Molecular modeling
KW - Protein interactions
UR - http://www.scopus.com/inward/record.url?scp=84961157096&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84961157096&partnerID=8YFLogxK
U2 - 10.1007/s11011-016-9798-x
DO - 10.1007/s11011-016-9798-x
M3 - Article
C2 - 26851955
AN - SCOPUS:84961157096
SN - 0885-7490
VL - 31
SP - 249
EP - 255
JO - Metabolic Brain Disease
JF - Metabolic Brain Disease
IS - 2
ER -